Drug trial for liver injury or liver failure
Part of Digestive system clinical trials.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old (or up to 65–70 depending on the stage).
- You have liver injury or liver failure based on specific blood test patterns (including ALT and bilirubin levels).
- Your abnormal liver blood tests have been happening for a limited time (for some groups, no more than 90 days/60 days).
- You must use effective birth control from screening until 6 months after the last study drug dose.
- You can sign the consent form and follow study visits and instructions (or a legal guardian/witness can sign if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
This trial tests whether a stem cell infusion made from umbilical cord tissue can help people with severe liver failure caused by hepatitis B. The stem cells may reduce liver damage and improve recovery.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new Acute Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.